Among the medications used for T2D, glipizide (sulfonylurea), repaglinide (insulin secretagogue), and nateglinide (insulin secretagogue) targeted KCNJ11 and ABCC8. This evidence concerns the gene KCNJ11 and type 2 diabetes mellitus.